1. Home
  2. RVMDW vs MTH Comparison

RVMDW vs MTH Comparison

Compare RVMDW & MTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVMDW
  • MTH
  • Stock Information
  • Founded
  • RVMDW N/A
  • MTH 1985
  • Country
  • RVMDW United States
  • MTH United States
  • Employees
  • RVMDW 443
  • MTH N/A
  • Industry
  • RVMDW
  • MTH Homebuilding
  • Sector
  • RVMDW
  • MTH Consumer Discretionary
  • Exchange
  • RVMDW Nasdaq
  • MTH Nasdaq
  • Market Cap
  • RVMDW N/A
  • MTH N/A
  • IPO Year
  • RVMDW N/A
  • MTH 1988
  • Fundamental
  • Price
  • RVMDW $0.35
  • MTH $183.36
  • Analyst Decision
  • RVMDW
  • MTH Hold
  • Analyst Count
  • RVMDW 0
  • MTH 8
  • Target Price
  • RVMDW N/A
  • MTH $200.14
  • AVG Volume (30 Days)
  • RVMDW N/A
  • MTH 373.3K
  • Earning Date
  • RVMDW N/A
  • MTH 10-29-2024
  • Dividend Yield
  • RVMDW N/A
  • MTH 1.64%
  • EPS Growth
  • RVMDW N/A
  • MTH 2.15
  • EPS
  • RVMDW N/A
  • MTH 22.10
  • Revenue
  • RVMDW N/A
  • MTH $6,433,727,000.00
  • Revenue This Year
  • RVMDW N/A
  • MTH $3.71
  • Revenue Next Year
  • RVMDW N/A
  • MTH $7.40
  • P/E Ratio
  • RVMDW N/A
  • MTH $8.30
  • Revenue Growth
  • RVMDW N/A
  • MTH N/A
  • 52 Week Low
  • RVMDW N/A
  • MTH $129.42
  • 52 Week High
  • RVMDW N/A
  • MTH $213.98
  • Technical
  • Relative Strength Index (RSI)
  • RVMDW N/A
  • MTH 38.20
  • Support Level
  • RVMDW N/A
  • MTH $163.00
  • Resistance Level
  • RVMDW N/A
  • MTH $187.56
  • Average True Range (ATR)
  • RVMDW 0.00
  • MTH 6.51
  • MACD
  • RVMDW 0.00
  • MTH -1.73
  • Stochastic Oscillator
  • RVMDW 0.00
  • MTH 42.50

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: